Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis
Evaluate Initial Safety of the HemiBridge™ System in Guided Spinal Growth Treatment of Progressive Idiopathic Scoliosis
The purpose of this clinical trial is to study a new method of treatment for patients who are
 diagnosed with idiopathic scoliosis and have abnormal and increasing curvature of the spine.
 The treatment consists of the surgical implantation of a new medical device called the
 "HemiBridge™ Clip". This medical implant device has never been used in humans. SpineForm,
 LLC, the developer of the HemiBridgeTM System has designed this scientific clinical trial, to
 evaluate the safety of the use of this device in humans. Information collected from patients
 treated with this new device shall be used to determine the initial safety of the new device.

 The FDA has approved the use of the HemibridgeTM System for this research study in 6 (six)
 pediatric patients who have idiopathic scoliosis.

 This procedure is intended to stop additional curvature of the spine by redirecting growth of
 the bones of the spine (vertebrae). To accomplish this, the patient undergoes a surgical
 procedure to securely attach small metal clips (HemiBridge™ Clips) to the outer side of each
 vertebra involved in the curvature. The HemiBridge™ Clip forms a "bridge" between each
 vertebra and is intended to hold the vertebrae in place to prevent the spine from curving any
 further.
Significance Spinal deformity fusion treatment involves some of the most costly and invasive
 procedures in orthopaedics. The development of an effective treatment method to avoid fusion
 is needed. Many pediatric spine specialists concur that growth modulation displays compelling
 pre-clinical and clinical data that must be studied further. While bracing is the only
 non-operative modality with any evidence of effectiveness for idiopathic scoliosis, its level
 of effectiveness compared to observation or natural history remains inconclusive. Research
 has been published for over 50 years, yet conflicting literature reports both successes and
 failures. Most literature consists of retrospective reports of bracing experience, with
 little commonality relative to existing conditions at the time bracing is initiated,
 documentation of compliance and basis for judging success.

 The U.S. Preventative Services Task Force (USPSTF) is an independent panel of private-sector
 experts in primary care and prevention. The Task Force was convened by the U.S. Public Health
 Service to systematically review the evidence of effectiveness of clinical preventive
 services. One of their charges was to evaluate the evidence supporting the practice of school
 screening for adolescent idiopathic scoliosis. After systematically reviewing the literature
 to date, their policy statement issues in 1992, and updated in 1996 states "…There is
 inadequate evidence to determine whether brace therapy limits the natural progression of the
 disease in a significant proportion of cases, as most studies suffer from selection bias,
 lack of internal control groups, inadequate follow-up, small sample sizes, and lack of health
 outcome measures."

 There is no Level One evidence to support the practice of bracing, and clinicians are left
 with conflicting and questionable inferences regarding bracing effectiveness. Some clinicians
 believe the evidence favors a decrease in the rate of curve progression, and based on this
 assumption, over half the states in the U.S. have mandated school screening programs for the
 detection and early treatment of scoliosis. On the other hand, groups such as the USPSTF, its
 British and Canadian counterparts and many individual practitioners worldwide feel the
 evidence is inconclusive and are therefore ambivalent about brace treatment.

 Due to the variability in published results on brace effectiveness, researchers in the United
 States and Canada have commenced a randomized multi-center trial of bracing versus no bracing
 to determine the effectiveness of brace wear in the treatment of idiopathic scoliosis (BRAIST
 Study). This study, which was initiated in 2007 in the United States, is being performed
 under the auspices of the US National Institutes of Health (NIH) and Canadian Institute of
 Health. In the Netherlands, a randomized multi-center study comparing bracing to observation
 is also underway.

 While bracing treatment is non-invasive and preserves growth, motion and function of the
 spine, it does not correct the deformity. In addition, the brace pressure on the rib cage and
 the influence on the chest wall in a growing child create concerns. Some scoliosis patients
 wear a brace for as long as five years only to learn that brace treatment failed and then
 recommended to endure major fusion surgery and recovery.

 When surgery (fusion and instrumentation) is required for scoliosis, internal fixation of the
 spine to achieve correction and bony fusion is performed. Surgical correction via posterior
 fusion is typically performed for curves greater than 40 - 50°, often with accompanying
 discectomy and release of the anterior longitudinal ligaments for curves greater than 75°.
 Smaller incisions or use of portals for anterior surgery became available in the early 1990's
 with video-assisted thoracoscopic surgery (VATS). Potential advantages include less muscular
 and chest wall disruption, less impact on pulmonary function, quicker recovery time and
 smaller scars. Arlet (2000) completed a meta-analysis of 10 articles with a total of 151
 patients, where VATS was utilized in scoliosis surgery. Of the 151 patients, 18% (27
 complications) experienced major and minor complications, including major bleeding (3),
 prolonged ventilation (10), pulmonary complications (6), intercostal neuralgia (number not
 specified), aborted procedure (3), and one each chylothorax, infection, and tachycardia. A
 conclusion could not be drawn as to whether the complication rate is increased or decreased
 with VATS. The correction rate was similar to open thoracotomy.

 Scoliosis fusion surgery involves extensive posterior and/or anterior spine exposure with
 associated risks, frequent blood transfusions (2 to 4 units), high postoperative pain, loss
 of motion of the treated segment, and slow rehabilitation. The child also has potential
 life-long complications that do not present for several years after surgery, including
 adjacent segment disease or degeneration that in many cases requires additional surgery.

 Andersen conducted a study of 100 braced and 115 surgical patients with idiopathic scoliosis
 10 years after the treatment was completed. The SF-36 scores (patient physical and mental
 health assessment) did not differ between the two groups; however, both group's scores were
 lower than age-matched normal controls. Results for the braced patients indicated that 17%
 felt that the brace was so unpleasant that they would rather take the chance of curve
 progression than wear a brace. Of the braced patients, 71% indicated that they would have
 preferred an operation (fusion) to a brace. More than two of three patients didn't wear the
 brace as prescribed due to skin irritation. Other investigators have refuted the impact of
 bracing on the quality of life.

 Thus, neither bracing nor surgical fusion treatments represent an ideal treatment of
 idiopathic scoliosis. As such, there is a need for idiopathic scoliosis treatments that
 address the population of patients whose curvature is unlikely to be corrected via bracing
 but for whom the risks of less invasive non-fusion surgical treatment may be exceeded by the
 potential benefit in avoiding lifelong progression or an extensive fusion surgery.

 The HemiBridge™ System is indicated for progressive idiopathic scoliosis (Lenke Type 1A or
 1B) in skeletally immature (Risser Grade 0 and triradiate cartilage open) patients by
 mechanically modulating spinal growth (hemiepiphysiodesis) and arresting spinal deformity
 progression without the need for spinal fusion. The HemiBridge™ System is intended to be
 placed at contiguous levels through an anterior thoracoscopic procedure on the convex side of
 a main thoracic curve that measures 25° to 40°, where the end of the vertebrae of the curve
 spans levels inclusive of or between T3 and L1. The HemiBridge™ System is intended for males
 and females with a chronologic age of 10 years and older. Females with an Atlas Matching bone
 age ≥ 8 years and 10 months not to exceed 13 years (or pre-menarche) and males with an Atlas
 Matching bone age ≥ 10 years not to exceed 15 years.

 Innovation The study device, named the HemiBridgeTM System, is the result of extensive
 pre-clinical research and development initiated by Donita Bylski-Austrow, PhD and Eric Wall,
 MD both of Cincinnati Children's Hospital Medical Center and the University of Cincinnati.
 Research and development of the study device to date has used an interdisciplinary team,
 including pediatric spine surgeons, engineers, scientists and regulatory experts. This team
 has helped define the compressive loading required to alter growth, tested prototype devices
 in preclinical models, improved the test articles for clinical use, and confirmed repeatable
 in-vivo results in compliance with FDA Good Laboratory Practices. This process has led to the
 approval of a study device that has achieved FDA and IRB approvals to begin clinical phase
 testing.

 The HemiBridge System's innovation is in its ability to apply mechanical hemiepiphysiodesis
 to redirect spine growth and developed to accommodate adolescent physiologic loading while
 remaining securely fastened to the spinal motion segment. Additionally, the System includes
 innovative patient safety and surgeon interface features. The surgical technique and
 instrumentation were co-developed by SpineForm LLC and the Orthopaedics Department at
 Cincinnati Children's Hospital Medical Center.

 The application of mechanical hemiepiphysiodesis to treat progressive scoliosis challenges
 the use of external bracing and/or observation (watchful waiting). Comparing the pooled rates
 for these two non-operative interventions shows no clear advantage of either approach;
 therefore, one cannot recommend one non-operative approach over the other to prevent the need
 for surgery in adolescent idiopathic scoliosis. Arresting curve progression with the
 HemiBridge System and avoiding fusion may significantly impact quality of life while reducing
 total lifetime patient care cost. Providing patients with a surgical alternative that is
 superior to the current non-operative standard of care is a paradigm shift that must be
 studied further to determine its safety and indications for use.

 The clinical study protocol design is limited to patients at the highest risk of progressing
 to needing multi-level fusion surgery. There are no medical devices cleared by the FDA to
 treat late juvenile or early adolescent onset of idiopathic scoliosis. The HemiBridge System
 is the first mechanical compression device FDA approved for pediatric investigational use.
 The proposed study is the first use in humans of the HemiBridge System. The clinical trials
 will enable the study sponsor to gather prospective information to continuously improve the
 product, its indications, the next study phase clinical protocol design and recommended
 surgical technique.
Inclusion Criteria:

 - Patients must meet all the criteria to be enrolled in this study:

 -  Trial subject population will involve patients who are skeletally immature, who have a
 diagnosis of idiopathic scoliosis with a single main thoracic curve Cobb angle 25° to
 40° and Lenke Type 1A or 1B.

 1. Chronologic age:

 -  Males ≥ 10 years

 -  Females ≥ 10 years

 2. Females pre-menarchal at screening examination

 3. Bone age as confirmed by radiographs of left hand and wrist according to the
 "Atlas Matching" method of Greulich and Pyle:

 -  Females: ≥ 8 years and 10 months not to exceed 13 years

 -  Males: ≥ 10 years not to exceed 15 years

 4. Skeletal immaturity (Risser grade 0 and the triradiate cartilage is open) as
 determined by standing, upright PA radiograph. If radiographic Risser grade
 results are indeterminate, the bone age from the Atlas Matching will prevail.

 5. Main thoracic Cobb angle of 25° to 40° as determined from standing, upright PA
 radiographs where the end vertebra are between or including T3 and L1 without
 wearing a brace

 6. Clinical diagnosis of idiopathic scoliosis with a single main thoracic curve as
 determined with measurement on standing posterior- anterior PA radiographs.

 -  Defined as a single thoracic curve where either: central sacral vertical
 line (CSVL) passes between the pedicles of the apical lumbar vertebra; or
 the CSVL touches the lumbar apical body(ies) (Lenke Type 1A or 1B,
 respectively)

 7. Achievable anatomical fit as determined by calibrated standing PA film:

 -  Disc height not exceeding 10 mm at each spinal level to be instrumented
 relative to location of the probable implant and

 -  Minimum central vertebral height that will accept the selected HemiBridge™
 Clip size at all levels planned for implants

 8. BMI < 30

 9. Physical and mental ability to undergo surgery with single lung ventilation

 10. Written informed assent from the patient

 11. Written informed consent from parent and/or legal guardian and authorization to
 use protected health information (by Sponsor, third party core lab and/or
 clinical evaluation committee)

 Exclusion Criteria:

 -  Patients who meet any of the exclusion criteria will not be enrolled.

 1. Non-idiopathic scoliosis

 2. Males and females chronological age < 10 years

 3. Triradiate cartilage is closed as determined on the standing PA radiograph at
 baseline screening

 4. Any curve type that does not meet definition of Lenke 1A or 1B

 5. Any main thoracic deformity that measures < 25° or > 40° Cobb angle

 6. Any main thoracic deformity that includes vertebral levels including and cranial
 to T2

 7. Any main thoracic deformity that includes vertebral levels including and caudal
 to L2

 8. Prior thoracotomy, thoracostomy or any spine surgery

 9. T3-T12 kyphosis > 40° (T4 or T5-T12 if visualization impaired at T3)

 10. Known history or existing malignancy, or any systemic or local infection

 11. Spinal cord abnormalities that require treatment

 12. Presence of neurological deficit (motor grades 0-4, sensory grades 0-1, reflexes
 grade 0 or 5 or asymmetry of deep tendon reflexes > 2 from right to left)

 13. Insulin-dependent diabetes

 14. Severe asthma

 15. Reduced pulmonary function, defined as < 60% of predicted value (Forced
 expiratory volume in one second [FEV1] divided by forced vital capacity [FVC]) or
 Subject has moderately severe or worse ventilatory limitation defined as < 60% of
 predicted value of the forced vital capacity [FVC] for age, race, sex and height
 (with height determined by arm span in patients with scoliosis and reference
 equations derived from the data of Wang et al 199329.)

 16. Cardiopulmonary or other systemic disease

 17. Bleeding disorder(s)

 18. Ataxia

 19. Documented HIV or hepatitis infection

 20. Family history of neurofibromatosis or Marfan's syndrome

 21. Medical contraindication to anesthesia

 22. Suspected or known allergy to titanium

 23. Not available for interval visits and long term follow-up exams